- United States
- /
- Healthcare Services
- /
- NasdaqCM:NUTX
Exploring Three Undervalued Small Caps With Insider Action Across Regions
The United States market has experienced a positive trend, with a 1.9% increase over the last week and a substantial 24% rise over the past year, while earnings are projected to grow by 15% annually in the coming years. In such an environment, identifying stocks that are potentially undervalued can be appealing to investors seeking opportunities for growth, especially when there is notable insider activity suggesting confidence in these companies' prospects.
Top 10 Undervalued Small Caps With Insider Buying In The United States
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Enovis | NA | 0.6x | 49.09% | ★★★★★★ |
| Financial Institutions | 8.6x | 2.7x | 43.73% | ★★★★★☆ |
| AVITA Medical | NA | 1.6x | 37.08% | ★★★★★☆ |
| Tennant | 28.5x | 1.0x | 48.09% | ★★★★☆☆ |
| Aldeyra Therapeutics | NA | NA | 46.93% | ★★★★☆☆ |
| German American Bancorp | 14.2x | 4.7x | 45.61% | ★★★☆☆☆ |
| Union Bankshares | 10.3x | 2.1x | 20.20% | ★★★☆☆☆ |
| Bank of the James Financial Group | 10.6x | 2.0x | 46.94% | ★★★☆☆☆ |
| New Peoples Bankshares | 9.4x | 2.2x | 41.83% | ★★★☆☆☆ |
| Douglas Emmett | 105.2x | 1.6x | 43.79% | ★★★☆☆☆ |
Underneath we present a selection of stocks filtered out by our screen.
Nutex Health (NUTX)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Nutex Health operates in the healthcare sector with divisions focusing on hospitals, real estate, and population health management, and has a market cap of approximately $1.02 billion.
Operations: The company derives its revenue primarily from the Hospital Division, with additional contributions from the Population Health Management Division. Over recent periods, it has experienced fluctuations in gross profit margin, reaching a peak of 67.09% and dipping to as low as -0.42%. Operating expenses are significant, impacting net income margins which have also varied widely from positive to negative figures across different quarters.
PE: 9.9x
Nutex Health, a company with a market presence in the healthcare sector, has shown significant revenue growth, reporting US$875.26 million for 2025 compared to US$479.95 million the previous year. Despite their volatile share price and reliance on external borrowing for funding, they exhibit insider confidence with recent buyback plans worth up to US$25 million. The company's earnings are forecasted to grow by 31.71% annually, suggesting potential future value despite past shareholder dilution challenges.
Univest Financial (UVSP)
Simply Wall St Value Rating: ★★★★☆☆
Overview: Univest Financial operates as a diversified financial services company with key operations in banking, insurance, and wealth management, and has a market capitalization of approximately $0.79 billion.
Operations: The company's revenue is primarily derived from its banking segment, contributing $271.14 million, with additional income from insurance at $22.48 million and wealth management at $31.98 million. Operating expenses are a significant component of the cost structure, with general and administrative expenses being a major part of these costs. Notably, the net income margin has shown fluctuations over time, reaching as high as 34.66% in certain periods before declining to 24.60% more recently.
PE: 10.8x
Univest Financial, a smaller player in the financial sector, has shown promising earnings growth with net income rising to US$22.75 million in Q4 2025 from US$18.94 million the previous year. Their recent share repurchase of 479,690 shares for US$15.42 million indicates strategic confidence in their valuation. Additionally, insider confidence is reflected through ongoing share purchases over recent months. With earnings projected to grow at 3.98% annually and consistent dividend payouts, Univest maintains a stable outlook amidst market fluctuations.
- Navigate through the intricacies of Univest Financial with our comprehensive valuation report here.
Examine Univest Financial's past performance report to understand how it has performed in the past.
Caledonia Mining (CMCL)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Caledonia Mining is a mining company primarily focused on the exploration and development of gold properties in Zimbabwe, with a market capitalization of approximately $0.13 billion.
Operations: Caledonia Mining generates revenue primarily through its operations, with recent figures showing a gross profit margin of 60.13%. The company's cost structure includes significant components such as Cost of Goods Sold (COGS) and operating expenses, which have varied across periods. Notably, non-operating expenses have also impacted net income margins in certain quarters.
PE: 8.3x
Caledonia Mining, a smaller company in the mining sector, has shown promising signs of being undervalued. Recent financials reveal a significant increase in sales to US$267.66 million and net income rising to US$55.22 million for 2025, indicating strong operational performance. Insider confidence is evident as Victor Gapare recently purchased 14,729 shares valued at approximately US$218,806. The company's dividend of 14 cents per share underscores its commitment to shareholder returns amid stable production guidance for 2026 at 72,000-76,500 ounces of gold despite previous production challenges.
- Get an in-depth perspective on Caledonia Mining's performance by reading our valuation report here.
Assess Caledonia Mining's past performance with our detailed historical performance reports.
Next Steps
- Get an in-depth perspective on all 53 Undervalued US Small Caps With Insider Buying by using our screener here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Nutex Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:NUTX
Nutex Health
Operates as a healthcare services and operations company in the United States.
Flawless balance sheet with proven track record.
Market Insights
Weekly Picks

When GPS fails: this small cap is fixing a $54B drone problem
From AI Infrastructure Plumber to Full-Stack AI Factory Architect

Aurelia Metals Limited — Transitioning Into a Higher-Quality Mid-Tier Producer

Is This strategic transformation of TTE? Significant re-rating potential
Recently Updated Narratives

IA Analysis

Sustainable Dominance: Justifying a $270 Fair Value

CRMD is trading at 5.9x trough-year EBITDA with the market ascribing near-zero value to two near-term pipeline events
Popular Narratives
NVIDIA will see a profit margin surge of 55% in the next 5 years

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
